TriSalus Life Sciences
TriSalus Life Sciences develops treatments for liver and pancreatic tumors, focusing on overcoming barriers to treatment through a platform approach that combines drug delivery technology with immunotherapy.
Services
TriSalus Life Sciences develops treatments for liver and pancreatic tumors, focusing on overcoming barriers such as intratumoral pressure and immunosuppression. The company employs a platform approach combining drug delivery technology with immunotherapy. TriSalus offers a proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method, along with the TriNav® Infusion System and the Pancreatic Retrograde Venous Infusion (PRVI™) System, both FDA-cleared for targeted delivery of therapeutics.
Products
TriSalus Life Sciences offers specialized products designed to enhance the delivery and efficacy of therapeutics for liver and pancreatic tumors. The TriNav® Infusion System is FDA-cleared for hepatic arterial infusion of liver tumors, while the Pancreatic Retrograde Venous Infusion (PRVI™) System is FDA-cleared for delivering therapeutics to the peripheral vasculature. In addition, the company is investigating nelitolimod (SD-101), a toll-like receptor 9 (TLR9) agonist, as a therapeutic candidate.
Clinical Trials
TriSalus Life Sciences conducts clinical trials for various forms of cancer, including uveal melanoma with liver metastases, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. The company aims to extend and improve the lives of patients with liver and pancreatic tumors by advancing their investigational platform which stimulates the immune system to boost the effectiveness of systemic immunotherapies.
Headquarters and Locations
TriSalus Life Sciences is headquartered in Westminster, CO. The company also operates additional locations in Bannockburn, IL, and Cranston, RI. These strategic locations support the company's mission to advance the treatment of liver and pancreatic tumors.
Mission and Partnerships
TriSalus Life Sciences is committed to extending and improving the lives of patients with liver and pancreatic tumors. The company engages in partnerships to explore combinations of immunotherapies and enhance patient outcomes. TriSalus aims to stimulate the immune system to improve the efficacy of systemic immunotherapies through its robust clinical trial programs and proprietary drug delivery technology.